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Background: The 8-aminoquinoline (8AQ) drug primaquine (PQ) is currently the only approved drug effective
against the persistent liver stage of the hypnozoite forming strains Plasmodium vivax and Plasmodium ovale as well
as Stage V gametocytes of Plasmodium falciparum. To date, several groups have investigated the toxicity observed
in the 8AQ class, however, exact mechanisms and/or metabolic species responsible for PQ’s haemotoxic and anti-
malarial properties are not fully understood.
Methods: In the present study, the metabolism of PQ was evaluated using in vitro recombinant metabolic enzymes
from the cytochrome P450 (CYP) and mono-amine oxidase (MAO) families. Based on this information, metabolite
identification experiments were performed using nominal and accurate mass measurements.
Results: Relative activity factor (RAF)-weighted intrinsic clearance values show the relative role of each enzyme to
be MAO-A, 2C19, 3A4, and 2D6, with 76.1, 17.0, 5.2, and 1.7% contributions to PQ metabolism, respectively. CYP 2D6
was shown to produce at least six different oxidative metabolites along with demethylations, while MAO-A
products derived from the PQ aldehyde, a pre-cursor to carboxy PQ. CYPs 2C19 and 3A4 produced only trace levels
of hydroxylated species.
Conclusions: As a result of this work, CYP 2D6 and MAO-A have been implicated as the key enzymes associated
with PQ metabolism, and metabolites previously identified as potentially playing a role in efficacy and haemolytic
toxicity have been attributed to production via CYP 2D6 mediated pathways.Background
Despite encouraging levels of progress in international
control efforts, as many as 3.3 billion people in the
world are at continued risk for malaria infection [1].
While Plasmodium falciparum exacts a greater burden
in mortality and morbidity, the impact of Plasmodium
vivax is also significant. It has been estimated that 40%
of the world’s population are at risk of vivax malaria
and, on the whole, more people are at risk of vivax than
falciparum malaria [2,3].* Correspondence: brandon.pybus@us.army.mil
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reproduction in any medium, provided the orA key component of continued control and eradication
efforts is the development of effective drugs for treat-
ment and prophylaxis. Only the 8-aminoquinoline (8-
AQ) class of compounds have demonstrated the ability
to target the key survival stages of the parasite — the
sleeping liver stages, or hypnozoites, of P. vivax and
Plasmodium ovale, and Stage V gametocytes of P. falcip-
arum, with primaquine (PQ) being the only drug from
this class in clinical use. Unfortunately, the use of 8-AQs
is limited by their tendency to cause haemolytic anaemia
in individuals with a genetic deficiency in glucose-6-
phosphate dehydrogenase (G6PD), an enzyme implicated
in the body’s defence against oxidative stress [4].
Although in use for several decades, PQ’s mechanisms
of efficacy and toxicity are not well understood and itstd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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mechanisms of efficacy/toxicity are believed to involve
the formation of reactive oxygen species or interference
by PQ and/or its metabolite(s) with electron transport
in the parasite [5]. Further, it is generally believed that
PQ’s haemolytic toxicity is due to one or more metabo-
lites and not the parent compound [6]. For example,
Link et al. show direct methaemoglobin (MHb) forma-
tion in canine hemolysates and purified human oxy-
haemoglobin (Hb) upon exposure to the putative PQ
metabolite 5-hydroxyprimaquine (5-HPQ) [7,8]. Further,
Ganesan et al. have recently demonstrated, in a human
erythrocyte-based model of PQ toxicity, the ability of
several CYPs, most notably 3A4, 2D6, and 2B6, to form
reactive oxygen species resulting in generation of
methaemoglobin [9]. MAOs have also been implicated
in PQ metabolism and may play a role in carboxypri-
maquine (CPQ) formation [10].
Elucidation of the fundamentals of PQ metabolism, in-
cluding the number, type, and relative contribution of
involved metabolic enzymes, as well as the metabolites
produced in each pathway, will help to determine if the
drug’s efficacy is inextricably linked to its toxicity in
G6PD-deficient individuals, or if future drug design
efforts could overcome toxicity, and potentially enhance
efficacy, by directing metabolism. To this end, a pheno-
typing study using the relative activity factor (RAF)
method of Crespi et al. was completed to determine the
number and type of mixed function oxidases involved in
PQ metabolism and the relative contribution of each
[11]. Overlap, if any, between the CYPs implicated in
toxicity by Ganesan et al. and any CYPs shown to
metabolize PQ to a great extent could help direct future
metabolism studies toward ultimately resolving the ques-
tion of which enzyme and which metabolite(s) is ultim-




Chemicals used were: primaquine diphosphate (Sigma, #
160393), nicotinamide adenine dinucleotide phosphate,
oxidized form (NADP) (Sigma, # 077K7000), acetonitrile
(Fisher Scientific, # 972970), glucose-6-phosphate (G6P)
(Sigma, # 046K3779), glucose-6-phosphate dehydrogen-
ase (G6PD) (Sigma, # 068K3795), and magnesium chlor-
ide (MgCl2) (Sigma, # 102K0154). The mobile phase for
LC separations consisted of acetonitrile, distilled water
and formic acid; all were of HPLC-grade.
Isoenzymes
Baculovirus-insect cell expressed recombinant Cytochrome-
P450 SupersomesW containing CYP-1A2 (BD Biosciences,
Billerica, MA, USA, # 18682), 2D6 (BD, # 16902), 3A4(BD, # 24175), 2C9 (BD, # 25315), 2C19 (BD, # 15466),
MAO-A (BD, # 31000), MAO-B (BD, # 36152), were
stored at −80°C until required and were rapidly thawed
by submersion in a 37°C water bath before use.
Enzyme activity screening
Cofactor concentrations were as follows in all experi-
ments: 1 U/ml G6PD, NADP 1.3 mM, G6P and MgCl2
3.3 mM, and 0.5 mg/mL CYP, MAO-A, MAO-B in
0.1 mM pH 7.4 phosphate buffered saline (PBS). Final
reaction volume was 1 mL. Reaction mixtures containing
all cofactors and enzymes were pre-warmed for 10 min
at 37°C, and reactions were started with the addition of
primaquine. Aliquots of 250 μL were quenched after 2 h
with an equal volume of cold acetonitrile. The resulting
samples were centrifuged at 13,000 rpm for 10 min and
the supernatant collected for analysis. Each experiment
was conducted with an n of four to eight. Error was
represented as the standard deviation.
Primaquine analysis
LC-MS analysis for phenotyping studies and enzyme ac-
tivity were performed using a Flux Rheos 2000 pump
(Flux Instruments AG, Switzerland) coupled with a CTC
PAL autosampler (LEAP Technologies, Carrboro, NC,
USA) and a Micromass ZQ (now Waters Corp., Milford,
MA, USA) mass spectrometer. Initial gradient condi-
tions were 98% water and 2% acetonitrile, each with
0.1% formic acid. Organic content was raised from 2% to
40% over 3 min before returning to the initial conditions
for equilibration for subsequent injections. The MS
method detected primaquine (parent ion) by positive ion
electrospray ionization at a m/z of 259.88. Analytical
separations were achieved using a Waters X-Terra RP
5 cm x 2 mm, 3 μm C18 column, with a flow rate of
300 ml/min.
RAF determination
Sample stocks of testosterone (3A4) (Sigma, # 160393),
bufuralol (2D6) (Sigma, # UC168), S-mephenytoin
(2 C19) (Sigma, # UC175), and serotonin (MAO-A)
(Sigma, # H9523) at 10 mM in DMSO were diluted to a
final concentration of 1 μM into a mixture containing
0.5 mg/mL of pre-incubated pooled human liver micro-
somes (BD Biosciences, Billerica, MA, USA) or recom-
binant enzyme of interest, 1.3 mM NADP, 3.3 mM
MgCl2, and 0.1 M pH 7.4 PBS using a TECAN Genesis
RSP 150 (Tecan, Durham, NC, USA) robotic liquid
handler. The reaction was started with the addition of 1
U/mL G6PD. The mixture was incubated on a shaking
platform at 37°C, and aliquots were taken and quenched
with the addition of an equal volume of cold acetonitrile
at 0, 10, 20, 30 and 60 min. Samples were centrifuged at
3,700 rpm for 10 min at 20°C to remove debris. Sample
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culated using the equation:
RAF ¼ rate for probe substrate in HLMð Þ
 rate for a probe substrate with recombinant isoenzymeð Þ
[11].
Kinetic studies
Incubations containing cofactors, primaquine (ranging
from 0 μM to 40 μM), and enzyme (CYP, MAO-A,
MAO-B) were treated as above, but quenched after
30 min (to remain within linear range of activity) with
an equal volume of cold acetonitrile. Each experiment
was conducted with an n of four to eight. Experimental
data were fit to the Michaelis-Menten equation using
non-linear least squares approximation. Error was repre-
sented as the standard deviation.
Hepatocyte incubations
Pooled human hepatocytes and culture medium were
purchased from Celsis/IVT (Chicago, IL). Cultures in
suspension were initiated from cryopreserved vials using
InVitro HI incubation buffer. Cell viability was verified
under a microscope by trypan blue exclusion. Approxi-
mately 5.0x105/ml hepatocytes were incubated with PQ
for 2 h. Reactions quenched using two volumes cold
ACN.Figure 1 CYP, MAO-A & B activity plotted as % parent loss for PQ aft
10 mM, CYPs, MAOs were at 100 mg/ml, NADP was 1.3 mM, MgCl2 and G6
MAO-A show activity. Each experiment was done with an n of four to eighMetabolite identification
All isoenzyme incubations were performed as mentioned
in the enzyme activity screening section above, except
PQ was fixed at 50 μM to increase the chances of
detecting low-level metabolites, and incubations were
quenched after 1 hr. Hepatocyte incubations were per-
formed as outlined in the hepatocytes incubations sec-
tion. Metabolites in the accurate mass data were found
using AB Sciex MetabolitePilot™ software. The data were
searched using an algorithm that used all of the follow-
ing criteria for finding potential metabolites: predicted
metabolites, mass defects, and isotope pattern (all three
for typical phase I and phase II and combinations with
dealkylations), and also common fragment ions and neu-
tral losses found in the primaquine product ion
spectrum. The data were scored by four criteria with
user-selectable weighting: mass defect (20% of total) with
an all-or-nothing score; isotope pattern (10% of total);
MS/MS similarity and quality (30% of total); and mass
accuracy (40% of total). The last three scoring criteria
were given weighted values based on how close the
measure property matched theory. Most metabolites had
a score of 70% or better. The software allows for up to
five controls. The data were processed using three con-
trols (a time 0 sample, and two buffer blanks).
MetabolitePilot™ software also was used to help match
probable structures to the MS/MS spectra of potential
metabolites using its interpretation module. Using theer two-hour incubation. Concentrations were as follows: PQ was at
P were both 3.3 mM, and G6PD was 1 Unit/ml. 3A4, 2D6, 2 C19, and
t. Error reported as SD.
Table 1 Steady-State kinetic parameters and RAF weighted contributions for PQ metabolism
Km (mM) Vmax
a Vmax/Km
b RAFc Contributiond % Contributione
2D6 37± 3 35.2 ± 2.5 951.4 0.014 13.3 1.7
3A4 37 ± 2 3.6 ± 0.2 97.3 0.42 40.9 5.2
2 C19 52 ± 19 25.6 ± 9.5 492.3 0.24 118.2 17.0
MAO-A 17± 1 10.4 ± 0.5 615.4 0.97 596.9 76.1
a Values in picomoles per minute per picomole of enzyme.
b Values in nL/min/picomole of enzyme.
c RAF = (rate for probe subs. with HLM)/(rate for probe subs. with isoenzyme).
dContributioni = (rate of metabolism for unknown with isoenzyme).
e% Contributioni = (Contributioni/(
P
Contribution values))*100.
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low m/z fragments) of the fragment ions and a program
which allows for bond breakages, ring closures, and re-
arrangements while also using chemical logic, the pro-
gram presents possible structures for the fragments,
highlighting them within the proposed structure.
Results
Metabolic enzyme phenotyping
A panel of recombinant human metabolic enzymes
(CYPs and MAOs) was screened for activity against
10 μM PQ. To account for drift in signal and spontan-
eous parent loss, each time point was compared to a
PQ only (no enzyme present) sample incubated under
the same conditions. After two-hour incubations, only
2C19, 2D6, 3A4, and MAO-A showed significant activ-
ity as measured by the loss of PQ (10 to 30%) (Figure 1).
Each of the four enzymes that demonstrated activity
against PQ was subjected to a steady-state kineticFigure 2 CYPs, MAO-A steady-state kinetics with PQ. Intitial velocity (
from 0 to 40 mM, CYPs, MAOs were at 100 mg/ml, NADP was 1.3 mM, Mg
mixture was incubated for 30 min and quenched with cold ACN. Each expanalysis to determine Km and Vmax, as reported in
Table 1 and illustrated in Figure 2. As defined by Crespi
et al.., calculation of the relative activity factor (RAF)
from kinetic constants derived from cDNA expressed
isoenzymes allows for a determination of individual
contribution from each CYP to intrinsic clearance [11].
Briefly, each Vmax/Km was weighted in this method by
an experimentally determined constant (RAF) to ac-
count for the relative abundance of each CYP as
expressed in microsomes, as well as the relative activ-
ities of each isoenzyme preparation. RAF is calculated
as (rate for a probe substrate parent loss in HLM)/(rate
of probe substrate parent loss with the cDNA expressed
isoenzyme). RAF and a %-weighted contribution from
each of the enzymes tested are found in Table 1.
Weighting contributions by RAF normalizes for activity
of cDNA expressed isoenzymes both for activity in the
HLM component mixture and relative abundance of
each of the component isoenzymes in HLMs only.Vo) vs. PQ concentration. Concentrations were as follows: PQ was
Cl2 and G6P were both 3.3 mM, and G6PD was 1 Unit/ml. Reaction
eriment was done with an n of four to eight. Error reported as SD.
Table 2 Putative metabolites observed after one-hour incubation with recombinant human MAO-A, 2D6, 3A4, and 2
C19 with retention times (rt), observed m/z and transitions
Putative metabolite rt (min) m/z (transition) MAO-A 2D6 3A4 2 C19
Parent 6.98 260.3! 175.1 60 80 99 98
PQ-alcohol 8.2 261.3! 175.1 38
CPQ 8.4 275.3! 175.1 <1
Ox1 (quinoline core) 5.0 276.3! 191.1 5
Ox2 (quinoline core) 6.1 276.3! 191.1 6
Tabulated data represents % of the total chromatographic peak area for each component. These values provide a qualitative relative measure of the metabolites
produced in these incubations and should not be construed in any way as quantitative measurements.
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tion to in vivo systems, and these parameters should
only be used as an indication of gross contribution to
phase I metabolism.
Metabolite identification
While parent loss is an inherently less-sensitive means
of monitoring metabolic activity compared to metabolite
formation, it was chosen for these studies for two pri-
mary reasons. First, without a priori knowledge of which
metabolites would be observed and, therefore, with no
neat standards of the metabolites, it would be difficult toTable 3 Putative metabolites observed using accurate mass a
A, 2D6 with retention times (rt), observed m/z and transition
Putative Metabolite (2D6) Formula
Demethylation and Ketone formation C14H17N3O2
Demethylation and Ketone formation C14H17N3O2
Demethylation and Ketone formation C14H17N3O2
Di-Oxidation and Ketone Formation C15H19N3O4
Loss of CH2+Oxidation C14H19N3O2
Loss of C5H12N2+Di-Oxidation and Ketone Formation C10H7NO4
Oxidation C15H21N3O2
Loss of CH2 C14H19N3O
Oxidation C15H21N3O2
Loss of CH2 C14H19N3O
Oxidation C15H21N3O2
Oxidation & Ketone C15H19N3O3
Oxidation C15H21N3O2
Oxidation & Ketone C15H19N3O3
Oxidation C15H21N3O2
Oxidative Deamination to Ketone C15H18N2O2
Oxidation C15H21N3O2
Oxidative Deamination to Alcohol C15H20N2O2
Putative Metabolite (MAO-A) Formula
Loss of NH+Desaturation C15H18N2O
Oxidative Deamination to Alcohol C15C20N2O2
Metabolites observed after one-hour incubation with recombinant human 2D6 and
mass defect, peak area, and % total chromatographic area.develop appropriate analytical methods to monitor their
formation. Second, since all metabolites will presumably
have unique ionization characteristics compared to other
metabolites as well as the parent compound, no quanti-
tative conclusions could be made about the amount of
metabolite being formed viz. the absolute metabolic ac-
tivity of PQ. Consequently, it was decided that loss of
parent would be the most consistent metric across all
enzymes. This second point should also be kept in mind
in the following discussions of total chromatographic
peak area. Peak area is a function of a compound’s
ionization efficiency under the conditions of the analysis,fter one-hour incubation with recombinant human MAO-
s
m/z ppm rt (min) Peak Area % Area
260.139 0.1 0.74 5.26E + 04 0.7
260.139 −0.1 0.93 5.71E + 04 0.7
260.14 1.6 1.25 3.26E + 05 4.1
306.145 −0.1 1.31 3.19E + 03 0
262.155 −1 1.33 2.64E + 04 0.3
206.045 −1.1 1.45 1.48E + 04 0.2
276.171 0.6 1.96 8.10E + 04 1
246.16 −0.8 2.14 1.50E + 04 0.2
276.171 2.6 2.17 4.40E + 05 5.5
246.161 1.6 2.52 1.46E + 05 1.8
276.171 0.4 3.51 1.56E + 04 0.2
290.15 1.3 3.66 1.91E + 04 0.2
276.171 1.4 3.68 7.90E + 04 1
290.151 2.5 3.85 2.27E + 03 0
276.171 1 3.97 4.60E + 03 0.1
259.144 0.4 4.2 6.08E + 03 0.1
276.171 1.3 4.21 6.32E + 04 0.8
261.16 0.1 7.14 6.85E + 04 0.9
m/z ppm rt (min) Peak Area % Area
243.15 1.5 4.2 4.15E + 03 0
261.16 2.3 7.14 1.62E + 06 14.2
MAO-A with retention times (rt), observed m/z, ppm deviance from expected
Figure 3 Putative pathway to observed MAO-A mediated metabolites. The PQ alcohol (m/z 261.2) is formed via formic acid mediated
reduction of the aldehyde, whereas the m/z 243.1 is formed by aldehyde ring closure followed by formic acid reduction.
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The goal of this part of the study was to explore the var-
iety and the nature of the metabolites being formed by
the active enzymes, with the object being the differenti-
ation and prioritization of the key metabolic pathways
for further investigations towards an improved thera-
peutic index for PQ and other 8AQs. While unstable
intermediates may exist and may have been undetected
using the experimental methods described herein, it is
asserted by the authors that the observed metabolites
provide an adequate foundation for that stated purpose.
Preliminary nominal mass PQ metabolite identification
experiments were performed using recombinant human
CYPs 2D6, 3A4, and 2C19 and MAO-A and 50 μM PQ.
These higher concentrations of PQ as compared to the
phenotyping experiment were designed to increase the
chances of seeing low level metabolites. The data
showed a marked loss of parent with only MAO-A and
2D6 over the course of one-hour incubation period,
while 3A4 and 2 C19 left PQ largely intact with only the
formation of trace levels of oxidated and demethylated
metabolites. The major observed metabolite in MAO-Aincubations was consistent with de-amination and alco-
hol formation, while trace amounts of CPQ formation
were also observed (Table 2). CYP 2D6 incubations led
primarily to the formation of two isobaric metabolites
with an MS/MS fragmentation pattern consistent with
hydroxylation on the quinoline core (Table 2).
In order to confirm the identity of the metabolites
observed using nominal mass instrumentation, dupli-
cate preparations of the MAO-A and CYP 2D6 incuba-
tions were analysed using an AB Sciex TripleTOF™
5600 mass spectrometer with high resolution accurate
mass capabilities. Samples were analysed using a MDF
IDA (on-the-fly, mass defect, filtered information-
dependant acquisition) method in which the system
gives preference to ions whose m/z ratio matches the
expected mass defects of primaquine and its metabo-
lites for the generation of MS/MS spectra for confirm-
ation. Observations are summarized in Table 3. In
short, after incubation with MAO-A, the alcohol was
observed as in nominal mass experiments. In addition,
a second m/z consistent with a ring-closed form of the
expected aldehyde was also observed. As outlined in
Table 4 Putative metabolites observed using accurate mass after two-hour incubation with pooled human hepatocytes
with retention times (rt), observed m/z and transitions
Putative Metabolite (HH) Formula m/z ppm rt (min) Peak Area % Area
Loss of C5H11N and CH2 C9H8N2O 161.0704 −3.2 1.36 9.02E + 03 0.1
Loss of CH2+ Gluc. Conj. C20H27N3O7 422.1910 −2.9 1.94 3.87E + 03 0.0
Oxidation* C15H21N3O2 276.1706 −0.2 2.18 1.39E+ 04 0.2
Loss of CH2* C14H19N3O2 246.1603 0.8 2.52 4.06E+ 04 0.5
Ketone Formation C15H19N3O2 274.1552 0.9 2.64 5.30E + 03 0.1
Oxidation* C15H21N3O2 276.1705 −0.5 3.68 8.42E+ 03 0.1
Oxidation* C15H21N3O2 276.1705 −0.5 4.22 1.45E+ 04 0.2
Loss of NH+Oxidation and Gluc. Conj. C21H28N2O8 437.1916 −0.5 6.21 5.21E + 03 0.1
Carbamoyl Glucoronide C22H29N3O9 480.1971 −1.1 6.40 3.72E + 04 0.4
Oxidative Deamination to Acid C15H18N2O3 275.1402 4.3 7.14 6.65E + 05 7.4
Oxidative Deamination to Alcohol*** C15H20N2O2 261.1600 0.8 7.14 3.01E+ 04 0.3
Metabolites observed after two-hour incubation with pooled human hepatocytes with retention times (rt), observed m/z, ppm deviance from expected mass
defect, peak area, and % total chromatographic area. Bolded metabolites can be accounted for as arising from either 2D6 * or MAO-A** metabolism, or were
observed in both ***
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the by-product of reduction of the aldehyde by formic
acid present in the chromatographic mobile phase.
Incubations with 2D6 produced a variety of low level
(<10% chromatographic peak area) phenolic, quinone,
and demethylated metabolites (Figure 4). While recom-
binant enzyme incubations are a useful tool for cor-
relating metabolites with their pathways of formation,
they are not sufficiently predictive of the competitive
processes in the liver in in vivo circumstances. Conse-
quently, metabolite identification studies were also
performed following in vitro hepatocyte incubations.
Metabolites formed after two-hour incubations of PQ
with pooled human hepatocytes were identified with
accurate mass measurements and are listed in Table 4.
Comparison with recombinant enzyme studies shows
that of the 11 unique metabolites observed in hepato-
cytes, five could be directly attributed to the pathways
outlined for CYP 2D6 and MAO-A. Namely, three
phenolic metabolites were observed in hepatocytes,
which had masses and retention times identical to
ones observed after incubation with 2D6. The
summed chromatographic peak areas for these phenolic
metabolites accounted for less than 0.5% of the total.
The PQ alcohol also appeared as observed after incuba-
tion with MAO-A, and, to a much lesser extent, CYP
2D6. The total chromatographic peak area for this me-
tabolite was 0.3%. A demethylation, identified as occur-
ring at the 6-methoxy position was also observed. It
was identified as deriving primarily from the CYP 2D6
pathway and accounted for 0.1% of the total peak area.
The largest single metabolite observed was CPQ, at
7.4% of the total chromatographic peak area. Three glu-
coronide conjugates were also observed along with two,
as-of-yet, unidentified metabolites. Including CPQ as apresumptive by-product of aldehyde dehydrogenation,
metabolites directly attributable to MAO-A and CYP
2D6-mediated pathways accounted for more than 93%
of the total metabolite area observed after two-hour in-
cubation with hepatocytes.
Discussion
Isoenzyme activity screening and steady-state kinetic
data suggest that CYPs 3A4, 2D6, 2C19, and also MAO-
A all play a role in PQ metabolism. However, using the
RAF-weighted, steady-state kinetics approach to analyse
the data [11], MAO-A appears to be the predominant
enzyme involved in Phase I PQ metabolism, followed by
2C19, 3A4, and 2D6, respectively. Brossi et al proposed
a role for MAOs in the formation of the carboxy (CPQ)
metabolite, and demonstrated differential Ki values for
(+)-PQ and (−)-PQ [12]. Further, they directly demon-
strated CPQ formation in liver fractions containing only
MAOs. These observations appear to support the find-
ings of the present study, indicating a major role for
MAO-A, in particular, in PQ metabolism.
While 3A4 and 2C19 are commonly involved in the
metabolism of anti-malarial compounds [13], neither
MAO-A nor 2D6 are generally considered to be signifi-
cant contributors to anti-malarial drug metabolism.
However, in this study, metabolites directly observed in
MAO-A and 2D6 incubations accounted for more than
93% of the total metabolite peak area observed after in-
cubation with hepatocytes. It is also interesting to note
that several anti-malarials are known inhibitors of CYP
2D6, including chloroquine (CQ), quinine, and quinidine
[13,14].
Many of the metabolites identified here have been
observed during the decades of research into the metab-
olism of PQ [15-18]. Key new findings of the present
Figure 4 Putative pathway to observed CYP 2D6 mediated phenolic and quinone metabolites. Positional isomers on the quinoline core
have different observed retention times, but are isobaric; therefore individual peaks cannot be assigned for the six observed phenols.
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production from specific CYP or MAO mediated path-
ways. For example, while 3A4 and 2C19 cannot be de-
finitively eliminated from consideration as the source of
PQ’s haemolytic and/or therapeutic metabolites, this
study clearly demonstrates that 2D6 has a much greater
intrinsic affinity for the metabolism of PQ and, at equal
concentrations, produces a significantly higher amount
of phenolic metabolites than either of those isoforms.
The nature of the metabolites formed, includingphenolic metabolites of the type first identified by Idowu
et al., by CYP 2D6 is highly suggestive that 2D6 may ac-
count for the well documented haemolytic effects of the
drug and its efficacy, as several of the phenolic metabo-
lites observed have been shown to re-dox cycle in the
presence of NADPH and/or oxidoreductase [5,16]. This
is believed to be the first time that these metabolites
have been directly attributed to one single CYP pathway.
If this is the case, then it is unlikely that haemolytic tox-
icity could be separated from efficacy through medicinal
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ism, as the metabolite(s) responsible for each effect are
generated in the same pathway. This has important
implications for the efficacy of PQ as a treatment against
relapsing malaria in 2D6 polymorphs of the poor or
intermediate metabolizer phenotype, as prevalence of
the poor metabolizer phenotypes are noted to be as high
as 21% in some populations (German Caucasians) and
the intermediate metabolizer phenotypes are estimated
as high as 50% in others (Asians) [19]. Further, haemo-
lytic toxicity could be exacerbated in extensive metaboli-
zers. The formation of the alcohol and ring-closed form
of the aldehyde by MAO-A, suggests that this enzyme
acts to catalyze the first step in the pathway leading to
the formation of CPQ, the major metabolite of PQ found
in plasma, and ultimately drug clearance via the acyl glu-
coronide. It should be noted however that 2D6 produced
the alcohol to a much lower level. This provides evi-
dence that carboxy primaquine production may be
mediated by both MAO-A and to a lesser extent by CYP
2D6. Further investigation in this area is needed to de-
termine the effects of common CYP 2D6 and MAO-A
inhibitors and inducers on PQ’s efficacy and toxicity.
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